doi: 10.3389/fnagi.2022.1059017 Received 30 September 2022 Accepted 12 December 2022 Published 06 January 2023 Volume 14 - 2022 Edited by Panteleimon Giannakopoulos, Universit de Genve, Switzerland Reviewed by Aarti Mishra, AbbVie, United States
Despite some states offering limited coverage of GLP-1s to treat weight loss as far back as a decade ago, most states that currently provide coverage through taxpayer-funded Medicaid programs or state employee health plans have only opted to do so within the past five years
Aging Cell 15, 196207
(Prior studies have simply found a link between taking a GLP-1 receptor agonist and drinking lessbut didnt go so far as to actually prove that the medications caused people to drink less.) The new study, which was published in JAMA Psychiatry, could result in a future treatment for the more than 28 million American adults who struggle with alcohol-use disorder (AUD)
Further, Eggerthella levels were consistently higher and Sutterella levels were consistently lower in people with MDD (49, 51)
J Neurochem (2003) 86:54555